Different SNPs in Fasciola hepatica P-glycoprotein from diverse Latin American populations are not associated with Triclabendazole resistance

Mol Biochem Parasitol. 2018 Sep:224:57-60. doi: 10.1016/j.molbiopara.2018.07.005. Epub 2018 Jul 25.

Abstract

The use of Triclabendazole for controlling fasciolosis is compromised by increased drug resistance affecting livestock and humans. Although the mode of action of TCBZ is still unknown, putative candidates and markers of resistance have been advanced. A single nucleotide polymorphism (T687 G) in F. hepatica PGP was proposed as marker of resistance in a small scale study of European susceptible and resistant flukes, but the association was not found in Australian samples. The T687 G SNP was absent in more than 40 samples from 2 TCBZ-resistant and 3 susceptible isolates across Latin America here analyzed. While the American samples showed more variable SNPs than the previous ones, none of the SNPs detected showed a marked association with resistance. Analyzing the 42 kb of the FhPGP gene based on RNAseq data highlights that the variation has been underestimated, suggesting that more detailed efforts are needed in order to identify markers of resistance.

Keywords: Drug resistance; Fasciola hepatica; Latin America; P-glycoprotein; SNPs; Triclabendazole.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
  • Animals
  • Antiplatyhelmintic Agents / pharmacology*
  • Drug Resistance*
  • Fasciola hepatica / drug effects*
  • Fasciola hepatica / enzymology*
  • Fasciola hepatica / isolation & purification
  • Humans
  • Latin America
  • Polymorphism, Single Nucleotide*
  • Sequence Analysis, RNA
  • Triclabendazole / pharmacology*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antiplatyhelmintic Agents
  • Triclabendazole